News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alitair Pharmaceuticals Receives Orphan Drug Designation for Erdosteine® In Bronchiectasis


1/7/2014 9:06:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MORRISTOWN, N.J.--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidate, Erdosteine®, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES